EZH2 and central nervous system cancer: For H3.3-mutant tumours (e.g. paediatric gliomas), combining epigenetic drugs (e.g. EZH2 inhibitors for K27M or NSD inhibitors for K36M) with immunotherapy could enhance efficacy.